| abstract |
The invention relates to a new crystalline form (S) -2- (8 - ((5-chloropyrimidin-2-yl) (methyl) amino) -2-fluoro-6,7,8,9-tetrahydro-5H-pyrido [3 , 2-b] indol-5-yl) acetic acid, to pharmaceutical compositions containing such a crystalline form, and to the use of this crystalline form as drugs, especially as modulators of the CRTH receptor (chemotactic receptor homologous molecule expressed on Th2 cells ). |